TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35171317
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g meropenem, 6-h infusion
Study: 32418546
Drug: (-)-OSU6162 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (-)-OSU6162 treatment
Study: 33302116
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day elemental calcium
Study: 35817581
Drug: Individualised feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised feedback on potentially inappropriate prescribing (PIP) of bronchodilator inhalers; feedback included visualised medication histories and action-oriented messages, sent in July 2015, February 2016, and August 2016.
Study: 33397667
Drug: STRIDE intervention
Normalized name: Stridex
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRIDE intervention (6 weekly 1-hour sessions via videoconferencing)
Study: 33397667
Drug: Medication monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication monitoring control group (electronic pill bottle and usual oncology care)
Study: 38458208
Drug: Paracetamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol plus ibuprofen
Study: 32994371
Drug: Shuxuetong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong injection
Study: 35779553
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase (0.25 mg/kg to a maximum of 25 mg)
Study: 35779553
Drug: Alteplase (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (0.9 mg/kg to a maximum of 90 mg; 0.09 mg/kg as a bolus and then a 60 min infusion of the remaining 0.81 mg/kg)
Study: 34871098
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg QD
Study: 34871098
Drug: Delpazolid 400
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 400 mg BID
Study: 34871098
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg BID
Study: 34871098
Drug: Delpazolid 1200
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 1200 mg QD
Study: 34871098
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg BID
Study: 36228639
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice daily for 3 days and then 0.6 mg once daily for 25 days
Study: 36228639
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 28 days
Study: 36228639
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (Control for aspirin)
Study: 34628831
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral prednisone once a day for 14 days (Group A)
Study: 34628831
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg oral prednisone once a day for 14 days (Group B)
Study: 34628831
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral prednisone once a day for 14 days (Group C)
Study: 35152882
Drug: Endoscopic retrograde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic retrograde appendicitis therapy (ERAT)
Study: 39139457
Drug: D-penicillamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine therapy
Study: 34285165
Drug: 1.9 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 µg HA/AS03B
Study: 34285165
Drug: 0.9 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 µg HA/AS03C
Study: 34285165
Drug: 1.9 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9 µg HA/AS03C
Study: 34285165
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg HA/AS03C
Study: 34285165
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg HA/AS03D
Study: 33927696
Drug: Stepwise reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise reduction of 12.5 IU rec-FSH daily in the Study group (SG)
Study: 32470022
Drug: High H2
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High H2 water (containing 7 ppm of H2: 3.5 mg H2 in 500-mL water)
Study: 34060416
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine paste, administered once weekly for eight consecutive weeks
Study: 615916148
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral supplement containing 10mg lutein, 2mg zeaxanthin and 10mg meso-zeaxanthin for a period of 6 months
Study: 32629007
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (COMPASS trial)
Study: 32629007
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (IMRD-UK cohort)
Study: 32152202
Drug: hu14.18‐IL2 immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18‐IL2 immunotherapy (Group A)
Study: 32152202
Drug: hu14.18‐IL2 immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18‐IL2 immunotherapy (Group B)
Study: 34845502
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg abiraterone with a low-fat meal (LOW)
Study: 34845502
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg abiraterone fasting (STD)
Study: 34895218
Drug: Fevipiprant 150
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant 150 mg
Study: 34895218
Drug: Fevipiprant 450
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant 450 mg
Study: 32706124
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma, 10-week protocol
Study: 32706124
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma
Study: 32448894
Drug: Stopping prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping prophylaxis when the patient was virologically suppressed (two consecutive HIV RNA ≤ 400c/mL)
Study: 35361632
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of methylprednisolone intravenously for 3 consecutive days
Study: 33001206
Drug: Antibody titers
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody titers in sequential samples from serum donors recovering from COVID-19
Study: 33068350
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of houttuynia cordata (3 mL each time, once a day for 3 injections, then once every two days for 3 times)
Study: 33068350
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears and anti-inflammatory drugs
Study: 32446263
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (lower dosage) in cesarean-born neonates (CDL)
Study: 32446263
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (higher dosage) in cesarean-born neonates (CDH)
Study: 35217772
Drug: Exenatide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2.0 mg once weekly plus dapagliflozin 10 mg once daily
Study: 32091358
Drug: Accelerated vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated vaccine schedule (0 and 21 days)
Study: 32091358
Drug: Longer interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer interval vaccine schedule (0 and 60 days)
Study: 33122529
Drug: LMWH combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH combined with insulin
Study: 35854638
Drug: Palovarotene 10/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 10/5 mg
Study: 35854638
Drug: Palovarotene 5/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 5/2.5 mg
Study: 34475143
Drug: Prepectoral implant-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepectoral implant-based breast reconstruction (IBBR)
Study: 34475143
Drug: Subpectoral implant-based
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpectoral implant-based breast reconstruction (IBBR)
Study: 33415556
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and surgery
Study: 33589674
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (260, 510, and 770 mg/day) for 12 weeks
Study: 36069785
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) course (5-week duration)
Study: 36069785
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (MI) before treatment
Study: 36069785
Drug: Self-guided booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided booster lesson (1 month after treatment)
Study: 32092190
Drug: Sleep hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep hygiene control (in-person discussion and monthly phone calls)
Study: 34719577
Drug: Propranolol gel
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol gel 1%
Study: 34719577
Drug: Propranolol gel
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol gel 5%
Study: 34292643
Drug: ozanimod 0.46
Normalized name: ozanimod 0.46 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozanimod 0.46 mg or 0.92 mg daily
Study: 34292643
Drug: interferon β‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon β‐1a 30 µg weekly
Study: 36429671
Drug: Bi-weekly resilience-enhancement
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly resilience-enhancement program (four 2-h sessions)
Study: 33964898
Drug: Nomogram including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nomogram including T stage, N stage, grade, radiotherapy, and chemotherapy
Study: 35145209
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading dose caffeine (80 mg/kg)
Study: 35145209
Drug: Standard loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard loading dose caffeine (20 mg/kg)
Study: 33715788
Drug: Ischemic pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ischemic pressure (IP) with traditional treatment
Study: 33715788
Drug: Postisometric relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postisometric relaxation (PIR) with traditional treatment
Study: 32929337
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified, but implied standard treatment for UC.
Study: 36432574
Drug: Quinoa-enriched wheat-bread
Normalized name: quinoa oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinoa-enriched wheat-bread roll providing 20 g quinoa flour each day
Study: 34439234
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture (10 treatments within five weeks)
Study: 33047298
Drug: Dupilumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab with concomitant topical corticosteroids
Study: 35932644
Drug: Comparison cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison cohort (initiating methadone treatment alone)
Study: 32015261
Drug: 0.45 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/d oral conjugated equine estrogens (o-CEE)
Study: 32015261
Drug: 50 mcg/d
Normalized name: Natpara 50 MCG/Dose Cartridge, 14 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg/d transdermal 17β-estradiol (t-E2)
Study: 36193494
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Therapy (BMT) combined with Thoracic Endovascular Aortic Repair (TEVAR)
Study: 32500194
Drug: Intra-articular facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular facet steroid injection (IFSI)
Study: 32500194
Drug: Transforaminal steroid
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal steroid injection (TFSI)
Study: 32243719
Drug: Apple intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple intake (dose-response study)
Study: 35111046
Drug: Standard-dose GHX02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose GHX02
Study: 35111046
Drug: High-dose GHX02
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GHX02 and Standard-dose GHX02
Study: 33866196
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD therapy
Study: 34153117
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg once monthly
Study: 32897933
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone per day for 1 week
Study: 36179790
Drug: 120-second MicroPulse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-second MicroPulse Transscleral Laser Therapy (MPTLT)
Study: 36179790
Drug: 100-second MicroPulse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-second MicroPulse Transscleral Laser Therapy (MPTLT)
Study: 32576247
Drug: Individualized tonotopical
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized tonotopical fitting of a cochlear implant (CI) based on post-operative cone beam CT scan (CBCT)
Study: 36050653
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks)
Study: 34774080
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine JCM-16021
Study: 35926833
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) trivalent modified-live virus (MLV) respiratory vaccine with parenteral (PT) bivalent bovine viral diarrhea virus (BVDV) type I + II vaccine (INT)
Study: 35926833
Drug: Parenteral (PT)
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral (PT) pentavalent modified-live virus (MLV) respiratory vaccine (INJ)
Study: 35926833
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) trivalent modified-live virus (MLV) respiratory vaccine with parenteral (PT) BVDV type I + II vaccine (INT)
Study: 32405975
Drug: Sugammadex (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2 or 4 mg·kg‐1)
Study: 32405975
Drug: Neostigmine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (70 µg·kg‐1, maximum 5 mg)
Study: 36010858
Drug: Tip sheet
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tip sheet and oral advice
Study: 36010858
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral advice alone
Study: 33025447
Drug: Free pharmaceutical
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free pharmaceutical services provided in public hospitals
Study: 33491385
Drug: Single application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of 1% NaF-HF gel
Study: 33491385
Drug: Two applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two applications of 1% NaF-HF gel with a 7-day interval
Study: 33491385
Drug: Two applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two applications of 1% NaF-HF gel with a 6-month interval
Study: 32297937
Drug: Galactose (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactose (0.75 g/kg body mass) in a high-fat beverage
Study: 32297937
Drug: Glucose (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (0.75 g/kg body mass) in a high-fat beverage
Study: 32297937
Drug: Fructose (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (0.75 g/kg body mass) in a high-fat beverage
Study: 33196511
Drug: Anticoagulation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation and atorvastatin 40 mg daily
Study: 33196511
Drug: Anticoagulation alone
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation alone (with either warfarin or rivaroxaban)
Study: 32303884
Drug: Remimazolam induction
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam induction at 6 mg kg-1 h-1 (group A)
Study: 32303884
Drug: Remimazolam induction
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam induction at 12 mg kg-1 h-1 (group B)
Study: 32303884
Drug: Remimazolam maintenance
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam maintenance infusion up to 2 mg kg-1 h-1 for both groups
Study: 35104848
Drug: Omilancor 440
Normalized name: Omilancor
DrugBank: Omilancor (DB19277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omilancor 440 mg QD
Study: 35104848
Drug: Omilancor 880
Normalized name: Omilancor
DrugBank: Omilancor (DB19277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omilancor 880 mg QD
Study: 33050924
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9
Study: 33050924
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg, 1 tablet QD from day 0 to 9
Study: 33050924
Drug: Favipiravir 200
Normalized name: Favipiravir 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9
Study: 33050924
Drug: Telmisartan 20
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 20 mg, 1 tablet QD from day 0 to 9
Study: 33050924
Drug: Complex of
Normalized name: Binary complex of recombinant human insulin-like growth factor I and insulin-like growth factor binding protein 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days
Study: 32042407
Drug: Cod protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod protein hydrolysate (CPH) 10 mg/kg BW
Study: 32042407
Drug: Cod protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod protein hydrolysate (CPH) 40 mg/kg BW
Study: 32838661
Drug: Control (hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hydration therapy)
Study: 34036689
Drug: Group-cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-cognitive-behavioral therapy (CBT)
Study: 38866963
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 35390490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular activities of daily living)
Study: 32897035
Drug: Continuous molgramostim
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous molgramostim (300 μg once daily by inhalation)
Study: 34085873
Drug: Assessment and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment and feedback combined with vaccine communication training and behavioral nudges (vaccine commitment posters)
Study: 34085873
Drug: Parents of
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents of HPV vaccine-hesitant children
Study: 35295236
Drug: Lesogaberan 120
Normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesogaberan 120 mg modified release twice daily
Study: 35928056
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) on days one and two, followed by misoprostol (200 or 400 μg, vaginally, six-hourly, up to three doses in 12 h)
Study: 35928056
Drug: Mifepristone (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (one dose on day one) followed by misoprostol on day three (historical control)
Study: 35928056
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) on days one and two, followed by misoprostol
Study: 35797219
Drug: Additional anthracycline-containing
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional anthracycline-containing chemotherapy
Study: 34039277
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for monitoring patients under home oxygen therapy
Study: 35217351
Drug: Cathodal high-definition
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal high-definition tDCS (treatment group)
Study: 35215057
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges (two per day for 90 days) with regular oral hygiene
Study: 35215057
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (two per day for 90 days) with regular oral hygiene
Study: 34533249
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and ALES (artichoke leaf extract)
Study: 34533249
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Vitamin E